Ren Y, Shahbaba B, Stark CEL. Improving clinical efficiency in screening for cognitive impairment due to Alzheimer's.
ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2023;
15:e12494. [PMID:
37908438 PMCID:
PMC10613605 DOI:
10.1002/dad2.12494]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 09/19/2023] [Accepted: 09/26/2023] [Indexed: 11/02/2023]
Abstract
INTRODUCTION
To reduce demands on expert time and improve clinical efficiency, we developed a framework to evaluate whether inexpensive, accessible data could accurately classify Alzheimer's disease (AD) clinical diagnosis and predict the likelihood of progression.
METHODS
We stratified relevant data into three tiers: obtainable at primary care (low-cost), mostly available at specialty visits (medium-cost), and research-only (high-cost). We trained several machine learning models, including a hierarchical model, an ensemble model, and a clustering model, to distinguish between diagnoses of cognitively unimpaired, mild cognitive impairment, and dementia due to AD.
RESULTS
All models showed viable classification, but the hierarchical and ensemble models outperformed the conventional model. Classifier "error" was predictive of progression rates, and cluster membership identified subgroups with high and low risk of progression within 1.5 to 3 years.
DISCUSSION
Accessible, inexpensive clinical data can be used to guide AD diagnosis and are predictive of current and future disease states.
HIGHLIGHTS
Classification performance using cost-effective features was accurate and robustHierarchical classification outperformed conventional multinomial classificationClassification labels indicated significant changes in conversion risk at follow-upA clustering-classification method identified subgroups at high risk of decline.
Collapse